Published 2 months ago • loading... • Updated 2 months ago

Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease

Summary by Pharmacy Times

As an investigational monoclonal antibody, posdinemab targets the mid-domain of AD-specific phosphorylated tau.

6 Articles

All

Left

Center

Right

neurologylive.com

FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

Posdinemab, a monoclonal antibody that targets the mid-domain of Alzheimer disease-specific phosphorylated tau, is currently being investigated in a placebo-controlled phase 2b trial that employs a plasma biomarker as a screening tool.

2 months ago

Read Full Article

biopharminternational.com

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.

2 months ago

Read Full Article

GeneOnline News

Posdinemab Becomes J&J's Second FDA Fast Track Designation Targeting Phosphorylated Tau in Alzheimer’s Disease

J&J reported that the FDA has granted Fast Track designation to posdinemab, for the treatment of early Alzheimer’s Disease (AD).

2 months ago

Read Full Article

lifesciencesbc.ca

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease - Life Sciences British Columbia

Building on decades of the Company’s Alzheimer’s research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J’s commitment to Alzheimer’s disease development and the potential of its precision approach TITUSVILLE, NJ – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a pho…

2 months ago

Read Full Article

Pharmacy Times

Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease

As an investigational monoclonal antibody, posdinemab targets the mid-domain of AD-specific phosphorylated tau.

2 months ago

Read Full Article

psychiatrictimes.com

FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer Disease

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources6

Leaning Left0Leaning Right0Center0Last Updated2 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

psychiatrictimes.com broke the news in 2 months ago on Wednesday, January 8, 2025.

Sources are mostly out of (0)

Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease

6 Articles

6 Articles

FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

J&J Gets FDA Fast Track Designation for Alzheimer’s mAb, Posdinemab

Posdinemab Becomes J&J's Second FDA Fast Track Designation Targeting Phosphorylated Tau in Alzheimer’s Disease

Posdinemab Becomes J&J's Second FDA Fast Track Designation Targeting Phosphorylated Tau in Alzheimer’s Disease

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease - Life Sciences British Columbia

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease - Life Sciences British Columbia

Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease

Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease

FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer Disease

FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer Disease

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics